Drug Trial Radar · NCT04469920
Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function
Last checked: Nov 20, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Jul 16, 2020
Primary completion
Mar 21, 2022
Study completion Mar 21, 2022
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a Phase 1, Open-label Study of Participants with Hepatic Impairment, Cholestatic Liver Disease, and NASH with Advanced Fibrosis and Normal Hepatic Function
Conditions
- Hepatic Impairment
Interventions
Saroglitazar Magnesium 2 mgDrug
1 tablet, single dose at Day 1
Saroglitazar Magnesium 4 mgDrug
1 tablet, single dose at Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC from time zero to infinity (AUC0-∞)Time frame: Before dosing on Day 1 through Day 7
- AUC from time zero to the last quantifiable concentration (AUC0-t)Time frame: Before dosing on Day 1 through Day 7
- CmaxTime frame: Before dosing on Day 1 through Day 7
- TmaxTime frame: Before dosing on Day 1 through Day 7
- t1/2Time frame: Before dosing on Day 1 through Day 7
- CL/FTime frame: Before dosing on Day 1 through Day 7
- Vz/FTime frame: Before dosing on Day 1 through Day 7
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Indiana University School of Medicine
Indianapolis, Indiana
American Research Corporation at Texas Liver Institute
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.